Ultime notizie per Johnson & Johnson (NYSE:JNJ) Azioni

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

PDCO

Scopri le 3 azioni sanitarie con dividendi superiori al 3% consigliate dai migliori analisti di Wall Street.

Dividendi oltre il 3%? Le azioni scelte dai migliori analisti

Johnson & Johnson Submits Supplemental Biologics License Application To FDA Seeking Approval Of Subcutaneous Induction Regimen Of TREMFYA

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI&#xAE; reduced the risk of disease progression or death by 74 per cent compared to standard of care.1
TORONTO, Nov. 21, 2024 /CNW/ - Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1&nbsp;With this approval, CARVYKTI&#xAE; becomes the first and only B-cell Maturation Antigen&nbsp;(BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as second line.
CARVYKTI&#xAE; previously received a Notice of Compliance with conditions (NOC/c) from Health Canada for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment.1
Canada's Drug Agency (CDA-AMC) has recently recommended CARVYKTI&#xAE; for reimbursement with conditions for eligible patients who have received one to three prior lines of therapy. In its rationale for the recommendation, CDA-AMC pointed out that the CARTITUDE-4 trial demonstrated that treatment with CARVYKTI&#xAE;, compared to standard of care, was associated with statistically significant and clinically meaningful improvements in progression-free survival (PFS) in eligible patients. This builds on their prior recommendation for reimbursement with conditions for CARVYKTI&#xAE; in 2023 in eligible patients who have received at least three prior lines of therapy, based on the results of the CARTITUDE-1 trial. Johnson &amp; Johnson is actively working with the pan-Canadian Pharmaceutical Alliance to negotiate reimbursement for CARVYKTI&#xAE; to enable public access.

Biotech

General

Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are Refractory To Lenalidomide

Deep-pocketed investors have adopted a bullish approach towards Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JNJ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Johnson &amp; Johnson. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 47% leaning bullish and 47% bearish. Among these notable options, 9 are puts, totaling $347,775, and 12 are calls, amounting to $492,730.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $165.0 for Johnson &amp; Johnson during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson &amp; Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson &amp; Johnson's substantial trades, within a strike price spectrum from $95.0 to $165.0 over the preceding 30 days.
<h3>Johnson &amp; Johnson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732208636_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$22.6</td>
<td>$22.25</td>
<td>$22.25</td>
<td>$135.00</td>
<td>$100.1K</td>
<td>121</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.5</td>
<td>$21.75</td>
<td>$22.35</td>
<td>$135.00</td>
<td>$84.8K</td>
<td>121</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.19</td>
<td>$1.9</td>
<td>$1.92</td>
<td>$165.00</td>
<td>$58.8K</td>
<td>1.2K</td>
<td>307</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$9.7</td>
<td>$9.2</td>
<td>$9.2</td>
<td>$160.00</td>
<td>$45.9K</td>
<td>935</td>
<td>157</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.2</td>
<td>$8.4</td>
<td>$9.2</td>
<td>$160.00</td>
<td>$45.9K</td>
<td>935</td>
<td>157</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
After a thorough review of the options trading surrounding Johnson &amp; Johnson, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Johnson &amp; Johnson's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,352,484, the price of JNJ is up by 1.08%, reaching $154.77.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $176.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wolfe Research downgraded its action to Outperform with a price target of $190. 
&#x2A; An analyst from Guggenheim persists with their Neutral rating on Johnson &amp; Johnson, maintaining a target price of $162. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Johnson &amp; Johnson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity

In the current market session, Johnson &amp; Johnson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) share price is at $153.45, after a 0.22% increase. Moreover, over the past month, the stock decreased by 6.45%, but in the past year, went up by 0.40%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1732194011_0.png" alt="Past Year Chart" />

<h3>Comparing Johnson &amp; Johnson P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Johnson &amp; Johnson has a lower P/E than the aggregate P/E of 27.43 of the Pharmaceuticals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732194011_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Johnson & Johnson

<a href="https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html" title="https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html">https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html</a>

BNTX

MRNA

NVAX

U.S. CDC Says Flu, Covid-19, RSV Illnesses Are At Low Levels Right Now Overall In U.S., But We Expect Them To Increase In Coming Weeks; Expects Hospitalizations For Flu And Covid-19 To Start Increasing In Coming Weeks

<a href="https://www.bnnbloomberg.ca/business/international/2024/11/20/jj-merck-cut-jobs-in-china-as-local-competition-takes-toll/#:~:text=Both%20US%20drug%20giants%20have,diabetes%20unit%2C%20the%20people%20said.">https://www.bnnbloomberg.ca/business/international/2024/11/20/jj-merck-cut-jobs-in-china-as-local-competition-takes-toll/#:~:text=Both%20US%20drug%20giants%20have,diabetes%20unit%2C%20the%20people%20said.</a>
Johnson &amp; Johnson and Merck &amp; Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting from Beijing's campaign to drive down medical costs.
Both US drug giants have laid off employees in China in recent days, according to people familiar with the matter who asked not to be identified discussing internal matters. The J&amp;J cuts mainly impacted a division that sells products used in surgery, while Merck scaled back in its diabetes unit, the people said.&nbsp;
Chinese media outlets, which were first to report the redundancies, cited the J&amp;J layoffs to be as much as a fifth of its mainland workforce. J&amp;J employs nearly 10,000 people across some 90 cities in China, according to its website.&nbsp;
J&amp;J "has recently implemented organizational changes to optimise our business operations" in the country, a company spokesperson told Bloomberg in an email. J&amp;J remains committed to the "critical and growing" China market, the spokesperson added.&nbsp;
Merck didn't immediately reply to a request for comment outside regular business hours.&nbsp;
Multinational drug and medical device makers are grappling with narrower profit margins in China, largely due to the country's system of having companies bid to supply drugs and devices to public hospitals — known as volume-based procurement (VBP). The program has seen global pharmaceutical companies lose hospital contracts for their top off-patent drugs and devices to cheaper local suppliers, essentially putting their sales team out of work in those categories.
The layoffs add to turmoil in the pharmaceutical market in China. Once seen as a big market opportunity for global drugmakers to expand, they've come under regulatory pressure on multiple fronts. AstraZeneca, which has seen China revenue growth slow due in part to losing hospital contracts for its off-patent medicines, is facing a criminal investigation into allegedly illegal sales practices which has ensnared its China chief.&nbsp;
In a recent earnings call, J&amp;J executives acknowledged a "disproportionate impact from VBP" thanks to its being the largest medtech company in China. The layoffs are the first major round of redundancies affecting the company's surgery division, a person familiar with the matter said, though layoffs in other departments have been ongoing for some time.&nbsp;
Meanwhile, Merck is set to face off against local suppliers for generic versions of two major diabetes drugs – Januvia and Janumet – in the latest round of VBP tender submissions.&nbsp;

Management

Reported Earlier, "J&J, Merck Cut Jobs in China As Local Competition Takes Toll" - BNN Bloomberg

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis
74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24
Comprehensive results are being prepared for presentation at upcoming medical congresses
SPRING HOUSE, Pa., Nov. 18, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced positive topline results from <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4305031-1&amp;h=1172454155&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06095115&amp;a=ICONIC-LEAD">ICONIC-LEAD</a>a, a&nbsp;pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). The Phase 3 study met its co-primary endpoints of Psoriasis Area and Severity Index (PASI) 90b and Investigator's Global Assessment (IGA) of 0/1c response at week 16 and response rates continued to improve through week 24.1
Once daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds (64.7%) of patients treated with&nbsp;icotrokinra achieved IGA scores of 0/1 (clear or almost clear skin), and 49.6% achieved PASI 90, compared to 8.3% and 4.4% on placebo, respectively.1 Further increases in response rates continued to be observed at week 24, with 74.1% of patients treated with icotrokinra achieving IGA scores of 0/1, and 64.9%&nbsp;achieving PASI 90.1&nbsp;Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. A similar proportion of patients experienced adverse events (AEs) between icotrokinra and placebo, with 49.3% and 49.1% of participants experiencing a treatment emergent adverse event (TEAE) at week 16.1,2,3
Furthermore, positive topline results from the Phase 3 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4305031-1&amp;h=4201851419&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06095102&amp;a=ICONIC-TOTAL">ICONIC-TOTAL</a>d&nbsp;study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo.4 Comprehensive results from ICONIC-LEAD and ICONIC-TOTAL are being prepared for presentation at upcoming medical congresses and will be shared with health authorities in planned submissions.

Johnson & Johnson Announced Topline Results From ICONIC-LEAD, A Pivotal Phase 3 Investigational Study Of Icotrokinra, The First Targeted Oral Peptide That Selectively Blocks The IL-23 Receptor, In Adults And Adolescents 12 Years Of Age And Older With Moderate To Severe Plaque Psoriasis; Met Its Co-Primary Endpoints In Patients With Moderate To Severe Plaque Psoriasis; 74% Of Patients Achieved Clear Or Almost Clear Skin At Week 24

Deep-pocketed investors have adopted a bullish approach towards Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JNJ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Johnson &amp; Johnson. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 36% bearish. Among these notable options, 5 are puts, totaling $179,583, and 6 are calls, amounting to $286,331.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $150.0 and $175.0 for Johnson &amp; Johnson, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Johnson &amp; Johnson stands at 1397.38, with a total volume reaching 2,022.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Johnson &amp; Johnson, situated within the strike price corridor from $150.0 to $175.0, throughout the last 30 days.
<h3>Johnson &amp; Johnson Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731690074_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.98</td>
<td>$1.79</td>
<td>$1.86</td>
<td>$155.00</td>
<td>$93.0K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.1</td>
<td>$3.95</td>
<td>$4.1</td>
<td>$150.00</td>
<td>$57.2K</td>
<td>527</td>
<td>274</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.98</td>
<td>$2.97</td>
<td>$2.98</td>
<td>$150.00</td>
<td>$44.5K</td>
<td>5.9K</td>
<td>168</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$7.45</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$155.00</td>
<td>$44.4K</td>
<td>1.5K</td>
<td>74</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$19.8</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$172.50</td>
<td>$39.0K</td>
<td>0</td>
<td>20</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 4,081,493, with JNJ's price up by 1.18%, positioned at $153.66.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
<h3>What Analysts Are Saying About Johnson &amp; Johnson</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $176.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Guggenheim has decided to maintain their Neutral rating on Johnson &amp; Johnson, which currently sits at a price target of $162. 
&#x2A; An analyst from Wolfe Research downgraded its action to Outperform with a price target of $190. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Johnson & Johnson

<a href="https://www.publicnow.com/view/22AE89CB26FE0DB79B0EFE719C101906FA50D630" title="https://www.publicnow.com/view/22AE89CB26FE0DB79B0EFE719C101906FA50D630">https://www.publicnow.com/view/22AE89CB26FE0DB79B0EFE719C101906FA50D630</a>

CHMP Recommends Approval Of Janssen's Rybrevant (Amivantamab) And Lazcluze (Lazertinib) Combo For First-Line Treatment Of EGFR-Mutated Advanced NSCLC, Potentially Establishing New Standard Of Care Pending European Commission Approval

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/66585980a3067c00012c48c0/david-roman">Goldman Sachs analyst David Roman </a>initiated coverage on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral rating and announced a price target of $108. HealthEquity shares closed at $95.70 on Thursday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with an Underperform rating and announced a price target of $25. Pfizer shares closed at $26.02 on Thursday. <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/insights/analyst-ratings/24/10/41494343/analyst-expectations-for-mastecs-future">Stifel analyst Brian Brophy</a> initiated coverage on EMCOR Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Buy rating and announced a price target of $600. EMCOR shares closed at $498.11 on Thursday. <a href="https://www.benzinga.com/quote/EME/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Harry Read initiated coverage on Insight Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) with a Buy rating and announced a price target of $220. Insight Enterprises shares closed at $152.63 on Thursday. See how other analysts view this stock.</li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with an Outperform rating and announced a price target of $190. Johnson &amp; Johnson shares closed at $151.87 on Thursday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png" alt="" class="wp-image-650063" style="width:716px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169.png 1196w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Initiation

NSIT

This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wolfe Research analyst Alexandria Hammond initiates coverage on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform rating and announces Price Target of $190.

Wolfe Research Initiates Coverage On Johnson & Johnson with Outperform Rating, Announces Price Target of $190

President-elect Donald Trump picked Robert F. Kennedy Jr., known for his vaccine skepticism, as his nominee Thursday to lead the <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could">Department of Health and Human Services. </a>
This move, which comes after Kennedy ended his presidential campaign and endorsed Trump, positions the environmental activist to potentially reshape national health policies. The selection has stirred mixed reactions, particularly from public health experts, <a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">Politico</a> reports.
&#8220;For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health,&#8221; Trump said in a tweet announcing the decision. 
As Benzinga reported earlier this month, Kennedy has a history of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies. His selection as the nominee for HHS secretary comes against a backdrop of falling vaccination rates, which coincide with, in one example, 13 measles outbreaks in the U.S. so far this year. 
What Happened: Trump's decision is part of a broader promise to "let Kennedy go wild" with health and food policies, aiming to overhaul the HHS. Kennedy has expressed sharp criticisms of several health agencies.
Kennedy had hinted at the potential role of "health czar" in Trump&#8217;s administration. If he is confirmed, Kennedy's appointment could influence vaccine policy and the <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">direction of the CDC, FDA, and NIH.</a>
Also Read: <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">Will Trump&#8217;s Election Win Push S&amp;P 500 Even Higher In Final Weeks Of 2024? Over 75% Say&#8230;</a>
Kennedy's prospective role has already affected vaccine manufacturer stocks. Major vaccine-related companies saw declines in stock prices on Thursday due to the uncertainty surrounding Kennedy&#8217;s influence on health policy.
Key companies impacted include:
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) down 5.62% to $39.77.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 2.62% to $26.02.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) down 0.89% to $151.87.</li>
<li>AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) down 0.38% to $65.04.</li>
<li>Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) down 7.02% to $7.22.</li>
</ul>
Why It Matters: Kennedy's views on vaccines and health oversight agencies stand in stark contrast to established medical consensus. His appointment could alter public health directives, with some analysts predicting potential shifts in FDA regulatory independence and vaccine guidelines. 
The impact may extend beyond policy, shaping public trust in health systems amid ongoing debates over vaccine safety.
Kennedy, while indicating he has no plans to "take away anybody's vaccines," continues to be a polarizing figure. Vaccine-related stocks may experience ongoing volatility as the Trump administration finalizes its health policy agenda.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock.

Equities

Government

Regulations

Health Care

Politics

Movers

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower

Johnson & Johnson's Nipocalimab Achieves Over 77% IgG Reduction And Significant Clinical Improvement In Phase 2 Sjögren's Disease Study; Gains FDA Breakthrough Therapy Designation

Johnson & Johnson MedTech Announces Exclusive Commericla Distribution Agreement In U.S. With Responsive Arthroscopy To Expand Sports Soft Tissue Solution

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) has filed a lawsuit against a U.S. government agency over a contentious <a href="https://www.benzinga.com/topic/pharmaceuticals">disagreement about payment methods</a>.
What Happened: The legal spat stems from the federal 340B Drug Pricing Program, which provides discounted medications to hospitals <a href="https://www.benzinga.com/general/biotech/24/08/40560227/johnson-johnson-aims-new-policy-for-hospital-payments-under-340b-drug-discount-program-related-to" target="_blank" rel="noreferrer noopener">serving vulnerable patients</a>.
The pharmaceutical giant <a href="https://fingfx.thomsonreuters.com/gfx/legaldocs/egvbjoronvq/JJ%20Health%20Care%20Systems%20v%20Becerra%2020241112.pdf" target="_blank" rel="noreferrer noopener">argues</a> that the program has strayed from its original intent and has become dominated by well-funded hospitals and for-profit entities. This includes large pharmacy chains and pharmacy benefit managers, leading to abuses that undermine patient benefits.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40316445/medicare-costs-for-johnson-johnsons-psoriasis-drug-stelara-double-when-obtained-at-pharmacies" rel="noreferrer noopener">Medicare Costs For Johnson &amp; Johnson&#8217;s Psoriasis Drug Stelara Double When Obtained at Pharmacies</a>
The 340B Program was established in 1992. It was designed to support low-income and uninsured patients by enabling certain healthcare providers to purchase outpatient drugs at reduced prices.
Manufacturers must enter a Pharmaceutical Pricing Agreement (PPA) with the Department of Health and Human Services (HHS) to sell drugs at discounted rates. This allows them to qualify for Medicare and Medicaid reimbursements.
However, Johnson &amp; Johnson contends that the program, now the second-largest federal drug initiative after Medicare, has been exploited by entities not intended initially as beneficiaries, sidelining patients.
In August 2024, Johnson &amp; Johnson proposed a new rebate-based pricing model in response to growing concerns over program integrity.
This model would shift from upfront discounts to rebates issued upon verification of purchase and dispense data, aimed at curbing duplicate discounting and improving transparency.
Initially, the rebate model would apply only to two of Johnson &amp; Johnson&#8217;s drugs and to disproportionate share hospitals (DSH)—large, resource-rich hospitals that, despite comprising less than 10% of covered entities, account for nearly 78% of 340B purchases.
Why It Matters: Johnson &amp; Johnson points to findings from audits conducted by the Health Resources and Services Administration (HRSA), which revealed significant non-compliance by covered entities, including unauthorized use of 340B-priced drugs and duplicate discounts.
From 2012 to 2019, HRSA audits found hundreds of violations involving diversion of drugs and overlapping Medicaid rebates.
Johnson &amp; Johnson&#8217;s attempts to audit covered entities also met resistance, with several refusing to produce records despite statutory obligations, further highlighting program abuses.
However, HRSA resisted the plan, threatening to terminate Johnson &amp; Johnson&#8217;s PPA and impose significant penalties. This prompted the company to suspend the model&#8217;s implementation, citing HRSA&#8217;s &#8220;severe and disproportionate&#8221; sanctions. Johnson &amp; Johnson argues that HRSA&#8217;s stance contradicts statutory provisions and the agency&#8217;s stated goals for program transparency.
Johnson &amp; Johnson&#8217;s lawsuit seeks a declaration that HRSA&#8217;s attempts to block the rebate model are unlawful and an injunction to prevent enforcement actions related to the proposed model.
The company emphasizes that program abuses will continue without adjustments like its rebate plan at the expense of the patients it was meant to serve.
Price Action: Johnson &amp; Johnson stock is down 0.37% at $152.08 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41932978/cisco-and-ltimindtree-join-forces-to-fortify-hybrid-work-security-with-cutting-edge-solutions" target="_blank" rel="noreferrer noopener">Cisco And LTIMindtree Join Forces To Fortify Hybrid Work Security with Cutting-Edge Solutions</a></li>
</ul>

Large Cap

Legal

Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study
A greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants on average who received nipocalimab 15 mg/kg compared to participants who received placebo
Nipocalimab was granted BTD in hemolytic disease of the fetus and newborn earlier this year, making this the second time Johnson &amp; Johnson's nipocalimab has received this designation
SPRING HOUSE, Pa., Nov. 11, 2024 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe Sjögren's disease (SjD), a debilitating and chronic autoantibody disease with high prevalence, for which no approved advanced treatments are available.1,2,3,4 Nipocalimab is the only investigational therapy to secure this designation in SjD. This regulatory milestone is the second time BTD has been granted for nipocalimab; the first was granted <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4299694-1&amp;h=1171220494&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Fjohnson-johnsons-nipocalimab-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-individuals-at-high-risk-for-severe-hemolytic-disease-of-the-fetus-and-newborn-hdfn&amp;a=in+February">in February</a> for the treatment of alloimmunized&nbsp;pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN).

Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High Prevalence, For Which No Approved Advanced Treatments Are Available

Johnson & Johnson Submits Regulatory Applications To FDA And EMA Seeking Approval Of A New Indication Of DARZALEX FASPRO In The US And DARZALEX Subcutaneous Formulation In The EU

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and its primary competitors in the Pharmaceuticals industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Johnson &amp; Johnson Background</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson &amp; Johnson</td>
<td>26.10</td>
<td>5.42</td>
<td>4.37</td>
<td>3.8%</td>
<td>$5.38</td>
<td>$15.51</td>
<td>5.25%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>83.66</td>
<td>51.76</td>
<td>17.18</td>
<td>6.98%</td>
<td>$2.25</td>
<td>$9.27</td>
<td>20.43%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>33.90</td>
<td>26.54</td>
<td>11.87</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>18.64</td>
<td>4.93</td>
<td>4.39</td>
<td>7.5%</td>
<td>$5.61</td>
<td>$9.94</td>
<td>8.93%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>30.99</td>
<td>5.01</td>
<td>4.06</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>36.48</td>
<td>1.68</td>
<td>2.61</td>
<td>4.96%</td>
<td>$7.25</td>
<td>$12.44</td>
<td>31.2%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>32.02</td>
<td>14.69</td>
<td>8.51</td>
<td>13.37%</td>
<td>$1.05</td>
<td>$1.69</td>
<td>11.02%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>22.67</td>
<td>4.01</td>
<td>1.82</td>
<td>-0.41%</td>
<td>$1.17</td>
<td>$5.62</td>
<td>-1.66%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>22.96</td>
<td>0.96</td>
<td>1.46</td>
<td>1.25%</td>
<td>$380.28</td>
<td>$781.73</td>
<td>12.75%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.30</td>
<td>3.49</td>
<td>3.55</td>
<td>4.18%</td>
<td>$23.9</td>
<td>$47.77</td>
<td>16.51%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.88</td>
<td>1.83</td>
<td>2</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>43.05</td>
<td>8.90</td>
<td>9.61</td>
<td>7.56%</td>
<td>$0.05</td>
<td>$0.18</td>
<td>47.69%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>3.13</td>
<td>8.25</td>
<td>0.64</td>
<td>112.72%</td>
<td>$0.4</td>
<td>$0.92</td>
<td>4.15%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>18.98</td>
<td>2.29</td>
<td>3.50</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>29.59</td>
<td>10.33</td>
<td>5.48</td>
<td>14.58%</td>
<td>$35.56</td>
<td>$72.24</td>
<td>14.79%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By closely studying Johnson &amp; Johnson, we can observe the following trends: 
<ul>
<li>
With a Price to Earnings ratio of 26.1, which is 0.88x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market participants.
</li>
<li>
The current Price to Book ratio of 5.42, which is 0.52x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
</li>
<li>
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 4.37, which is 0.8x the industry average.
</li>
<li>
The company has a lower Return on Equity (ROE) of 3.8%, which is 10.78% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.38 Billion is 0.15x below the industry average, suggesting potential lower profitability or financial challenges.
</li>
<li>
With lower gross profit of $15.51 Billion, which indicates 0.21x below the industry average, the company may experience lower revenue after accounting for production costs.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of 5.25% compared to the industry average of 14.79%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730991650_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio gauges the extent to which a company has financed its operations through debt relative to equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Johnson &amp; Johnson stands in comparison with its top 4 peers, leading to the following comparisons:
<ul>
<li>
Johnson &amp; Johnson is in a relatively stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.51.
</li>
<li>
This implies that the company relies less on debt financing and has a more favorable balance between debt and equity.
</li>
</ul>
<h3>Key Takeaways</h3>
For Johnson &amp; Johnson, the PE, PB, and PS ratios are all low compared to its peers in the Pharmaceuticals industry, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest that the company may be facing challenges in generating profits and growth compared to its industry counterparts. This could be a concern for investors looking for higher returns.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Industry Comparison: Evaluating Johnson &amp; Johnson Against Competitors In Pharmaceuticals Industry

Guggenheim analyst Vamil Divan maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and raises the price target from $156 to $162.

Guggenheim Maintains Neutral on Johnson & Johnson, Raises Price Target to $162

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

RPRX

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

Optimism over global healthcare sector rises: Jefferies

Franklin Income Fund Q3 2024 Commentary

Eli Lilly Stock: Unexpected Developments (Rating Downgrade)

Zevra Niemann-Pick disease type C drug Miplyffa now available

3 Dividend Kings So You Can Sleep Well At Night

Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of a subcutaneous induc...

JNJ seeks FDA approval of subcutaneous induction regimen of Tremfya

Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and others

Johnson & Johnson seeks FDA approval for its ulcerative colitis treatment

Sanofi (SNY) is planning changes to its 340B plan on how it gives discounts to certain hospitals, planning to require institutions to provide pharm...

Sanofi planning changes to 340B hospital drug discount plan, WSJ reports

Sanofi becomes latest drugmaker to challenge HHS over 340B drug-discount program

ABBV

AMGN

AZNCF

BIIB

COMM

GILD

GLAXF

INTC

MPLN

SNYNF

TMUS

VOYA

ZVRA

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Johnson & Johnson

Notizie

Ultime notizie per Johnson & Johnson (NYSE:JNJ) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO